Evidence map›Paper›PMID 41251836›Full record

ArticleCancer immunology, immunotherapy : CII2025

CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8

Zhaojia Wu, Zhenyu Yang, Tauqeer Iftikhar, Gary Groot, Scot C Leary, Nicolas Baniak, Shahid Ahmed, Mark Bosch, Michael Moser, Wenjun Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhaojia Wu *Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Zhenyu Yang *Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Tauqeer Iftikhar *Saskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Gary GrootDepartment of Surgery, University of Saskatchewan, Saskatoon, SK, Canada.
Scot C LearyDepartment of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK, Canada.
Nicolas BaniakDepartment of Pathology, University of Saskatchewan, Saskatoon, SK, Canada.
Shahid AhmedSaskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Mark BoschSaskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Michael MoserDepartment of Surgery, University of Saskatchewan, Saskatoon, SK, Canada.
Wenjun ZhangDivision of Biomedical Engineering, University of Saskatchewan, Saskatoon, SK, Canada.
Junhong JiangDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou, China. jiangjunhong1969@suda.edu.cn.
Jim XiangSaskatoon Cancer Center, Saskatchewan Cancer Agency, Saskatoon, SK, Canada. jim.xiang@usask.ca.

Funding

CoMRAD grant from the College of Medicine, University of Saskatchewan #1-427754Saskatchewan Cancer Agency Operating Grant with funds donated to the Cancer Foundation of Saskatchewan #1-425532the Cancer Research Society Charlotte Legare Memorial Fund Operating Grant 1055181The Innovation Research Project of Medical and Health Care of Suzhou CXYJ2024A07the Science and Technology Project of Suzhou Municipal Health Commission LCZX202234
6 · The paper itself

Abstract

backgroundMelanoma is one of the deadliest forms of skin cancer. Irreversible electroporation (IRE) is an innovative, non-thermal ablation technology for treating irresectable solid cancers. However, most IRE treatments are incapable of cancer eradication and only temporarily prolong patient survival.

methodsIn this study, we developed a novel IRE + Combo treatment regimen that combines IRE-ablation with Combo-adjuvant [CpG, anti-PD-L1 antibody (PD-L1-Ab) and CD40-agonist] and investigated its anti-tumor immunity in a mouse BL6-10

resultsWe demonstrated that inclusion of the CD40-agonist in the IRE + Combo treatment regimen promoted a more robust CD8

conclusionTaken together, this study establishes that the CD40-agonist greatly potentiates the efficacy of IRE-ablation for metastatic melanoma by promoting unexpected CD8

Indexed as

CD40 AntigensCD8-Positive T-LymphocytesDendritic CellsElectroporationMelanomaMelanoma, ExperimentalSkin NeoplasmsAnimalsAntigens, CDCell Line, TumorFemaleHumansIntegrin alpha ChainsMiceMice, Inbred C57BLalpha E integrinsAntigens, CDCD40 AntigensIntegrin alpha ChainsCD103+ TRM cellCD40-agonistCD8+CD103+ cDC1IRE-ablationMetastatic melanomaPD-1 blockade

Identifiers

PMID41251836
PMCPMC12627309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.